Vijendra Swarup, MD
Clinical Cardiac Electrophysiology · Phoenix, AZNPI 1427051929
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 74.2% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2020 at $64,587 and has fallen 88.0% since, to $7,763 in 2025. Among clinical cardiac electrophysiology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,630 payments — averaging $114.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$139K
- Boston Scientific$19K
- Biosense Webster, Inc.$9K
- Impulse Dynamics (USA) Inc.$4K
- Medtronic$3K
- Novartis$2K
- plus $11K from 44 others
Across 452 payments — averaging $10,883 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2.2M
- Abbott$1.2M
- Cordis US CORP.$472K
- Boston Scientific$308K
- Cvrx, Inc.$273K
- Livanova USA, Inc.$162K
- plus $264K from 9 others
What the payments were for
- Consulting fees$82,59344%
- Travel & lodging$53,04028%
- Food & beverage$51,72228%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$114,318
- WATCHMAN Access System$12,451
- AVEIR$4,730
- OPTIMIZER$3,999
- Watchman$2,654
- Carto 3$2,384
- Confirm Rx$1,862
- GENERAL - THERAPIES$1,502
- Rapiblyk$1,357
- EnSite Precision Cardiac Mapping System$1,162
- Micra$1,156
- Farapulse$1,005
- EVERA MRI XT DR SURESCAN$951
- Merlin Connectivity and Remote$898
- AMPLATZER$751
- Barostim Neo System$736
- OPTIMIZER SMART SYSTEM$520
- ENSITE$443
- Assurity Pacemaker$434
- remede System$417
How this compares
$187,369 in reported general payments places this provider in the 90th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
See all clinical cardiac electrophysiology providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 350 | $450,612 |
| EntrestoSacubitril/Valsartan | 130 | $182,098 |
| JardianceEmpagliflozin | 105 | $128,781 |
| FarxigaDapagliflozin Propanediol | 100 | $105,681 |
| XareltoRivaroxaban | 80 | $85,736 |
| SotalolSotalol Hcl | 604 | $11,049 |
| Metoprolol Succinate | 477 | $6,934 |
| Rosuvastatin Calcium | 650 | $6,317 |
| Praluent PenAlirocumab | 12 | $5,967 |
| Spironolactone | 686 | $5,035 |
| Losartan Potassium | 467 | $4,380 |
| Amiodarone Hcl | 60 | $3,199 |
| Atorvastatin Calcium | 362 | $2,895 |
| Ezetimibe | 114 | $2,891 |
| Eplerenone | 29 | $2,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $450,612350 claims |
| NovartisEntresto | $1,983 | $182,098130 claims |
| Boehringer IngelheimJardiance | $396 | $128,781105 claims |
| AstraZenecaFarxiga | $542 | $105,681100 claims |
| Johnson & JohnsonXarelto | $458 | $85,73680 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
Other clinical cardiac electrophysiology in Phoenix
- Akash MakkarPhoenix$318K
- Jonathan WeissPhoenix$290K
- Yoaav KrauthammerPhoenix$238K
- Paul HaasPhoenix$136K
- Praneeth KatrapatiPhoenix$76K
- Komandoor SrivathsanPhoenix$57K
- Divyashree VarmaPhoenix$49K
- Sushmitha PatibandlaPhoenix$47K
- Mohamed AbdelrahmanPhoenix$45K
- James KnellerPhoenix$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.